九芝堂(000989) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥827,800,209.66, representing a year-on-year growth of 24.85%[10] - Net profit attributable to shareholders was ¥30,949,386.14, a significant increase of 150.01% compared to the same period last year[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥21,203,193.10, up by 69.43% year-on-year[10] - Basic earnings per share for the reporting period was ¥0.0368, reflecting a growth of 150.34% compared to the same period last year[10] - Total operating revenue for the third quarter reached ¥827,800,209.66, an increase of 25% compared to ¥663,053,265.80 in the previous period[64] - Net profit for the quarter was ¥30,411,780.63, significantly higher than ¥11,484,960.99 from the same period last year, marking an increase of over 165%[70] - The company's operating revenue for the current period reached ¥979,391,942.10, an increase of 17.5% compared to ¥834,002,329.26 in the previous period[92] - Net profit attributable to the parent company was ¥228,064,338.95, up from ¥188,830,349.05, reflecting a growth of 20.8%[88] - Total profit for the current period was ¥288,769,867.05, compared to ¥243,912,038.90 in the previous period, marking an increase of 18.4%[88] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,103,996,820.47, an increase of 4.06% compared to the previous year[10] - Cash and cash equivalents increased by 185.69% to 84,974.51 million yuan due to the redemption of financial assets and an increase in short-term loans[26] - Total assets reached CNY 5.10 billion, up from CNY 4.90 billion, indicating an increase of about 4.3%[56] - Total liabilities increased to CNY 1.22 billion from CNY 912.97 million, representing a growth of approximately 33.9%[56] - The company's total assets increased to ¥9,698,510,611.35, compared to ¥9,325,979,969.90 in the previous period, representing a growth of approximately 4%[64] - Total liabilities rose to ¥976,891,198.26, up from ¥705,006,289.94, indicating an increase of about 39%[64] - Total assets amounted to CNY 4,904,747,670.66, with current assets at CNY 2,527,004,175.79 and non-current assets at CNY 2,377,743,494.87[112] - Total liabilities reached CNY 912,970,073.37, with current liabilities at CNY 842,699,065.28 and non-current liabilities at CNY 70,271,008.09[115] Cash Flow - The net cash flow from operating activities was ¥190,622,805.59, an increase of 23.75% year-on-year[10] - The company reported a net cash flow from operating activities of 49,293.99 million yuan, a decrease of 21.48% compared to 62,775.29 million yuan in the previous year, primarily due to increased accounts receivable and procurement expenses[29] - Operating cash flow generated from business activities amounted to ¥492,939,861.32, a decrease of 21.4% compared to ¥627,752,868.40 in the previous period[98] - Cash inflow from investment activities totaled ¥3,656,267,683.98, significantly higher than ¥1,856,300,940.47 in the prior period, marking an increase of 96.6%[101] - Cash inflow from operating activities reached ¥936,582,956.49, up from ¥749,962,006.14, reflecting a growth of 24.9%[104] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,782[14] - The largest shareholder, Li Zhenguo, holds 39.25% of the shares, amounting to 341,202,854 shares[14] Research and Development - The company’s research and development expenses rose by 11.73% to 7,771.32 million yuan, reflecting increased investment in R&D activities[26] - Research and development expenses for the quarter were ¥37,354,821.85, compared to ¥26,633,112.61 in the previous year, showing an increase of approximately 40%[67] - Research and development expenses increased to ¥14,012,771.65, up 69% from ¥8,281,672.52 in the previous period, highlighting a focus on innovation[73] - Research and development expenses rose to ¥28,120,004.57, up from ¥22,927,654.62, indicating a growth of 22.5%[92] Investment Activities - The company plans to invest an additional 15,000 million yuan into a merger fund, increasing its total investment to 60,000 million yuan, with a total fund size of 90,000 million yuan[30] - The company reported a significant loss of 5,408.33 million yuan in investment income, primarily due to amortization and losses from the acquisition fund's investment in Stemedica[26] - The company experienced a decrease in investment income, reporting a loss of ¥54,083,339.98 compared to a loss of ¥18,865,906.11 in the previous period[84] Other Financial Metrics - The weighted average return on net assets was 0.88%, an increase of 0.46 percentage points compared to the previous year[10] - The company received government subsidies amounting to ¥19,729,920.64 during the reporting period[10] - The company incurred interest expenses of ¥1,292,831.35, while interest income was ¥3,712,805.99, resulting in a net interest income of ¥2,419,974.64[84] - The company paid out ¥337,107,003.40 in dividends and interest, slightly up from ¥336,026,804.80 in the previous period[101]